Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension
Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
Status: Enrolling
Updated:  12/31/1969
Palatin Clinical Site 289
mi
from
Tiffin, OH
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension
Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
Status: Enrolling
Updated: 12/31/1969
Palatin Clinical Site 289
mi
from
Tiffin, OH
Click here to add this to my saved trials
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension
Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
Status: Enrolling
Updated:  12/31/1969
Palatin Clinical Site 227
mi
from
Oklahoma City, OK
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension
Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
Status: Enrolling
Updated: 12/31/1969
Palatin Clinical Site 227
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension
Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
Status: Enrolling
Updated:  12/31/1969
Palatin Clinical Site 227
mi
from
Oklahoma City, OK
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension
Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
Status: Enrolling
Updated: 12/31/1969
Palatin Clinical Site 227
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension
Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
Status: Enrolling
Updated:  12/31/1969
Palatin Clinical Site 267
mi
from
Allentown, PA
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension
Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
Status: Enrolling
Updated: 12/31/1969
Palatin Clinical Site 267
mi
from
Allentown, PA
Click here to add this to my saved trials
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension
Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
Status: Enrolling
Updated:  12/31/1969
Palatin Clinical Site 234
mi
from
Philadelphia, PA
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension
Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
Status: Enrolling
Updated: 12/31/1969
Palatin Clinical Site 234
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension
Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
Status: Enrolling
Updated:  12/31/1969
Palatin Clinical Site 240
mi
from
Pittsburgh, PA
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension
Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
Status: Enrolling
Updated: 12/31/1969
Palatin Clinical Site 240
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension
Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
Status: Enrolling
Updated:  12/31/1969
Palatin Clinical Site 278
mi
from
Lincoln, RI
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension
Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
Status: Enrolling
Updated: 12/31/1969
Palatin Clinical Site 278
mi
from
Lincoln, RI
Click here to add this to my saved trials
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension
Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
Status: Enrolling
Updated:  12/31/1969
Palatin Clinical Site 200
mi
from
Greer, SC
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension
Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
Status: Enrolling
Updated: 12/31/1969
Palatin Clinical Site 200
mi
from
Greer, SC
Click here to add this to my saved trials
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension
Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
Status: Enrolling
Updated:  12/31/1969
Palatin Clinical Site 275
mi
from
Chattanooga, TN
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension
Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
Status: Enrolling
Updated: 12/31/1969
Palatin Clinical Site 275
mi
from
Chattanooga, TN
Click here to add this to my saved trials
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension
Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
Status: Enrolling
Updated:  12/31/1969
Palatin Clinical Site 216
mi
from
Jackson, TN
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension
Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
Status: Enrolling
Updated: 12/31/1969
Palatin Clinical Site 216
mi
from
Jackson, TN
Click here to add this to my saved trials
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension
Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
Status: Enrolling
Updated:  12/31/1969
Palatin Clinical Site 161
mi
from
Memphis, TN
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension
Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
Status: Enrolling
Updated: 12/31/1969
Palatin Clinical Site 161
mi
from
Memphis, TN
Click here to add this to my saved trials
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension
Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
Status: Enrolling
Updated:  12/31/1969
Palatin Clinical Site 129
mi
from
Nashville, TN
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension
Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
Status: Enrolling
Updated: 12/31/1969
Palatin Clinical Site 129
mi
from
Nashville, TN
Click here to add this to my saved trials
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension
Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
Status: Enrolling
Updated:  12/31/1969
Palatin Clinical Site 235
mi
from
Arlington, TX
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension
Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
Status: Enrolling
Updated: 12/31/1969
Palatin Clinical Site 235
mi
from
Arlington, TX
Click here to add this to my saved trials
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension
Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
Status: Enrolling
Updated:  12/31/1969
Palatin Clinical Site 230
mi
from
Austin, TX
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension
Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
Status: Enrolling
Updated: 12/31/1969
Palatin Clinical Site 230
mi
from
Austin, TX
Click here to add this to my saved trials
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension
Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
Status: Enrolling
Updated:  12/31/1969
Palatin Clinical Site 113
mi
from
Dallas, TX
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension
Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
Status: Enrolling
Updated: 12/31/1969
Palatin Clinical Site 113
mi
from
Dallas, TX
Click here to add this to my saved trials
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension
Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
Status: Enrolling
Updated:  12/31/1969
Palatin Clinical Site 208
mi
from
Houston, TX
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension
Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
Status: Enrolling
Updated: 12/31/1969
Palatin Clinical Site 208
mi
from
Houston, TX
Click here to add this to my saved trials
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension
Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
Status: Enrolling
Updated:  12/31/1969
Palatin Clinical Site 269
mi
from
Draper, UT
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension
Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
Status: Enrolling
Updated: 12/31/1969
Palatin Clinical Site 269
mi
from
Draper, UT
Click here to add this to my saved trials
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension
Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
Status: Enrolling
Updated:  12/31/1969
Palatin Clinical Site 228
mi
from
West Jordan, UT
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension
Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
Status: Enrolling
Updated: 12/31/1969
Palatin Clinical Site 228
mi
from
West Jordan, UT
Click here to add this to my saved trials
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension
Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
Status: Enrolling
Updated:  12/31/1969
Palatin Clinical Site 284
mi
from
Newport News, VA
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension
Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
Status: Enrolling
Updated: 12/31/1969
Palatin Clinical Site 284
mi
from
Newport News, VA
Click here to add this to my saved trials
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension
Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
Status: Enrolling
Updated:  12/31/1969
Palatin Clinical Site 205
mi
from
Norfolk, VA
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension
Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
Status: Enrolling
Updated: 12/31/1969
Palatin Clinical Site 205
mi
from
Norfolk, VA
Click here to add this to my saved trials
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension
Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
Status: Enrolling
Updated:  12/31/1969
Palatin Clinical Site 213
mi
from
Richmond, VA
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension
Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
Status: Enrolling
Updated: 12/31/1969
Palatin Clinical Site 213
mi
from
Richmond, VA
Click here to add this to my saved trials
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension
Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
Status: Enrolling
Updated:  12/31/1969
Palatin Clinical Site 213
mi
from
Richmond, VA
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension
Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
Status: Enrolling
Updated: 12/31/1969
Palatin Clinical Site 213
mi
from
Richmond, VA
Click here to add this to my saved trials
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension
Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
Status: Enrolling
Updated:  12/31/1969
Palatin Clinical Site 214
mi
from
Seattle, WA
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension
Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
Status: Enrolling
Updated: 12/31/1969
Palatin Clinical Site 214
mi
from
Seattle, WA
Click here to add this to my saved trials
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension
Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
Status: Enrolling
Updated:  12/31/1969
Palatin Clinical Site 285
mi
from
Charleston, WV
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension
Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
Status: Enrolling
Updated: 12/31/1969
Palatin Clinical Site 285
mi
from
Charleston, WV
Click here to add this to my saved trials
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension
Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
Status: Enrolling
Updated:  12/31/1969
Palatin Clinical Site 400
mi
from
Vancouver,
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension
Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
Status: Enrolling
Updated: 12/31/1969
Palatin Clinical Site 400
mi
from
Vancouver,
Click here to add this to my saved trials
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension
Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
Status: Enrolling
Updated:  12/31/1969
Palatin Clinical Site 170
mi
from
Saint Louis, MO
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension
Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
Status: Enrolling
Updated: 12/31/1969
Palatin Clinical Site 170
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension
Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
Status: Enrolling
Updated:  12/31/1969
Palatin Clinical Site 259
mi
from
Moncks Corner, SC
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension
Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
Status: Enrolling
Updated: 12/31/1969
Palatin Clinical Site 259
mi
from
Moncks Corner, SC
Click here to add this to my saved trials
The Brave Initiative: Bringing Rehabilitation to American Veterans in an Enriched Environment
Harnessing Neuroplasticity to Promote Rehabilitation: Constraint-Induced (CI) Therapy for Traumatic Brain Injury (TBI)
Status: Enrolling
Updated:  12/31/1969
University of Alabama at Birmingham
mi
from
Birmingham, AL
The Brave Initiative: Bringing Rehabilitation to American Veterans in an Enriched Environment
Harnessing Neuroplasticity to Promote Rehabilitation: Constraint-Induced (CI) Therapy for Traumatic Brain Injury (TBI)
Status: Enrolling
Updated: 12/31/1969
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Electronic Alerts for Stroke Prevention in Patients With Atrial Fibrillation or Atrial Flutter
Alert-Based Computerized Decision Support for Stroke Prevention in High-Risk Hospitalized Patients With Atrial Fibrillation: A Randomized, Controlled Trial (AF-ALERT)
Status: Enrolling
Updated:  12/31/1969
Brigham and Women's Hosp
mi
from
Boston, MA
Electronic Alerts for Stroke Prevention in Patients With Atrial Fibrillation or Atrial Flutter
Alert-Based Computerized Decision Support for Stroke Prevention in High-Risk Hospitalized Patients With Atrial Fibrillation: A Randomized, Controlled Trial (AF-ALERT)
Status: Enrolling
Updated: 12/31/1969
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Evaluation of Potential Allergenicity of New Wheat Varieties
Evaluation of Potential Allergenicity of New Wheat Varieties
Status: Enrolling
Updated:  12/31/1969
Children's Hospital Colorado
mi
from
Aurora, CO
Evaluation of Potential Allergenicity of New Wheat Varieties
Evaluation of Potential Allergenicity of New Wheat Varieties
Status: Enrolling
Updated: 12/31/1969
Children's Hospital Colorado
mi
from
Aurora, CO
Click here to add this to my saved trials
Effects of Standing on Non-Ambulatory Children With Spinal Muscular Atrophy
Effects of Standing on Non-Ambulatory Children With Spinal Muscular Atrophy
Status: Enrolling
Updated:  12/31/1969
Gillette Children's Specialty Healthcare
mi
from
Saint Paul, MN
Effects of Standing on Non-Ambulatory Children With Spinal Muscular Atrophy
Effects of Standing on Non-Ambulatory Children With Spinal Muscular Atrophy
Status: Enrolling
Updated: 12/31/1969
Gillette Children's Specialty Healthcare
mi
from
Saint Paul, MN
Click here to add this to my saved trials
Clinical Trial of a Serious Game for Individuals With SCI/D
Evaluating the Effectiveness of a Serious Game to Enhance Self-Management Skills Among Adolescents and Young Adults With Spinal Cord Dysfunction
Status: Enrolling
Updated:  12/31/1969
University of Michigan Health System
mi
from
Ann Arbor, MI
Clinical Trial of a Serious Game for Individuals With SCI/D
Evaluating the Effectiveness of a Serious Game to Enhance Self-Management Skills Among Adolescents and Young Adults With Spinal Cord Dysfunction
Status: Enrolling
Updated: 12/31/1969
University of Michigan Health System
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
An Open Label Phase 2 Study of ManNAc in Subjects With GNE Myopathy
An Open-Label Phase 2 Study of ManNAc in Subjects With GNE Myopathy
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
An Open Label Phase 2 Study of ManNAc in Subjects With GNE Myopathy
An Open-Label Phase 2 Study of ManNAc in Subjects With GNE Myopathy
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Energetics and Function in Older Humans
Energetics and Function in Older Humans
Status: Enrolling
Updated:  12/31/1969
Baylor Metabolic Research Unit (MRU)
mi
from
Houston, TX
Energetics and Function in Older Humans
Energetics and Function in Older Humans
Status: Enrolling
Updated: 12/31/1969
Baylor Metabolic Research Unit (MRU)
mi
from
Houston, TX
Click here to add this to my saved trials
Clinical Utility of Serum Biomarkers for the Management of Neonatal Hypoxic Ischemic Encephalopathy (Control Levels)
Clinical Utility of Serum Biomarkers for the Management of Neonatal Hypoxic Ischemic Encephalopathy (HIE) Control Levels
Status: Enrolling
Updated:  12/31/1969
University of Florida
mi
from
Gainesville, FL
Clinical Utility of Serum Biomarkers for the Management of Neonatal Hypoxic Ischemic Encephalopathy (Control Levels)
Clinical Utility of Serum Biomarkers for the Management of Neonatal Hypoxic Ischemic Encephalopathy (HIE) Control Levels
Status: Enrolling
Updated: 12/31/1969
University of Florida
mi
from
Gainesville, FL
Click here to add this to my saved trials
Preventing Loss of Independence Through Exercise (PLIE) in Persons With Dementia
Preventing Loss of Independence Through Exercise (PLIE) in Persons With Dementia
Status: Enrolling
Updated:  12/31/1969
San Francisco VA Medical Center, San Francisco, CA
mi
from
San Francisco, CA
Preventing Loss of Independence Through Exercise (PLIE) in Persons With Dementia
Preventing Loss of Independence Through Exercise (PLIE) in Persons With Dementia
Status: Enrolling
Updated: 12/31/1969
San Francisco VA Medical Center, San Francisco, CA
mi
from
San Francisco, CA
Click here to add this to my saved trials
Therapeutic Potential for Aldosterone Inhibition in Duchenne Muscular Dystrophy
Therapeutic Potential for Aldosterone Inhibition in Duchenne Muscular Dystrophy
Status: Enrolling
Updated:  12/31/1969
Mattel Children's Hospital and David Geffen School of Medicine at UCLA
mi
from
Los Angeles, CA
Therapeutic Potential for Aldosterone Inhibition in Duchenne Muscular Dystrophy
Therapeutic Potential for Aldosterone Inhibition in Duchenne Muscular Dystrophy
Status: Enrolling
Updated: 12/31/1969
Mattel Children's Hospital and David Geffen School of Medicine at UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Therapeutic Potential for Aldosterone Inhibition in Duchenne Muscular Dystrophy
Therapeutic Potential for Aldosterone Inhibition in Duchenne Muscular Dystrophy
Status: Enrolling
Updated:  12/31/1969
University of Colorado
mi
from
Aurora, CO
Therapeutic Potential for Aldosterone Inhibition in Duchenne Muscular Dystrophy
Therapeutic Potential for Aldosterone Inhibition in Duchenne Muscular Dystrophy
Status: Enrolling
Updated: 12/31/1969
University of Colorado
mi
from
Aurora, CO
Click here to add this to my saved trials
Therapeutic Potential for Aldosterone Inhibition in Duchenne Muscular Dystrophy
Therapeutic Potential for Aldosterone Inhibition in Duchenne Muscular Dystrophy
Status: Enrolling
Updated:  12/31/1969
Ohio State University Medical Center
mi
from
Columbus, OH
Therapeutic Potential for Aldosterone Inhibition in Duchenne Muscular Dystrophy
Therapeutic Potential for Aldosterone Inhibition in Duchenne Muscular Dystrophy
Status: Enrolling
Updated: 12/31/1969
Ohio State University Medical Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Therapeutic Potential for Aldosterone Inhibition in Duchenne Muscular Dystrophy
Therapeutic Potential for Aldosterone Inhibition in Duchenne Muscular Dystrophy
Status: Enrolling
Updated:  12/31/1969
University of Utah
mi
from
Salt Lake City, UT
Therapeutic Potential for Aldosterone Inhibition in Duchenne Muscular Dystrophy
Therapeutic Potential for Aldosterone Inhibition in Duchenne Muscular Dystrophy
Status: Enrolling
Updated: 12/31/1969
University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Therapeutic Potential for Aldosterone Inhibition in Duchenne Muscular Dystrophy
Therapeutic Potential for Aldosterone Inhibition in Duchenne Muscular Dystrophy
Status: Enrolling
Updated:  12/31/1969
University of Kansas Medical Center
mi
from
Kansas City, KA
Therapeutic Potential for Aldosterone Inhibition in Duchenne Muscular Dystrophy
Therapeutic Potential for Aldosterone Inhibition in Duchenne Muscular Dystrophy
Status: Enrolling
Updated: 12/31/1969
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Therapeutic Potential for Aldosterone Inhibition in Duchenne Muscular Dystrophy
Therapeutic Potential for Aldosterone Inhibition in Duchenne Muscular Dystrophy
Status: Enrolling
Updated:  12/31/1969
Vanderbilt University Medical Center
mi
from
Nashville, TN
Therapeutic Potential for Aldosterone Inhibition in Duchenne Muscular Dystrophy
Therapeutic Potential for Aldosterone Inhibition in Duchenne Muscular Dystrophy
Status: Enrolling
Updated: 12/31/1969
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
The Safety of ahSC in Chronic SCI With Rehabilitation
The Safety of Autologous Human Schwann Cells (ahSC) in Subjects With Chronic Spinal Cord Injury (SCI) Receiving Rehabilitation
Status: Enrolling
Updated:  12/31/1969
University of Miami
mi
from
Miami, FL
The Safety of ahSC in Chronic SCI With Rehabilitation
The Safety of Autologous Human Schwann Cells (ahSC) in Subjects With Chronic Spinal Cord Injury (SCI) Receiving Rehabilitation
Status: Enrolling
Updated: 12/31/1969
University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
Plegridy Observational Program
Plegridy™ (Peginterferon β-1a) Real World Effectiveness and Safety Observational Program
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Homewood, AL
Plegridy Observational Program
Plegridy™ (Peginterferon β-1a) Real World Effectiveness and Safety Observational Program
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Homewood, AL
Click here to add this to my saved trials
Plegridy Observational Program
Plegridy™ (Peginterferon β-1a) Real World Effectiveness and Safety Observational Program
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Gilbert, AZ
Plegridy Observational Program
Plegridy™ (Peginterferon β-1a) Real World Effectiveness and Safety Observational Program
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Gilbert, AZ
Click here to add this to my saved trials
Plegridy Observational Program
Plegridy™ (Peginterferon β-1a) Real World Effectiveness and Safety Observational Program
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Berkeley, CA
Plegridy Observational Program
Plegridy™ (Peginterferon β-1a) Real World Effectiveness and Safety Observational Program
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Berkeley, CA
Click here to add this to my saved trials
Plegridy Observational Program
Plegridy™ (Peginterferon β-1a) Real World Effectiveness and Safety Observational Program
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Washington,
Plegridy Observational Program
Plegridy™ (Peginterferon β-1a) Real World Effectiveness and Safety Observational Program
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Washington,
Click here to add this to my saved trials
Plegridy Observational Program
Plegridy™ (Peginterferon β-1a) Real World Effectiveness and Safety Observational Program
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Delray Beach, FL
Plegridy Observational Program
Plegridy™ (Peginterferon β-1a) Real World Effectiveness and Safety Observational Program
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Delray Beach, FL
Click here to add this to my saved trials
Plegridy Observational Program
Plegridy™ (Peginterferon β-1a) Real World Effectiveness and Safety Observational Program
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Atlanta, GA
Plegridy Observational Program
Plegridy™ (Peginterferon β-1a) Real World Effectiveness and Safety Observational Program
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
Plegridy Observational Program
Plegridy™ (Peginterferon β-1a) Real World Effectiveness and Safety Observational Program
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Indianapolis, IN
Plegridy Observational Program
Plegridy™ (Peginterferon β-1a) Real World Effectiveness and Safety Observational Program
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials